{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:48:12Z","timestamp":1787330892137,"version":"build-2736575974"},"reference-count":85,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor with still poor prognosis. In this article, we focus on recent developments in the management of MPM including diagnosis, staging, biomarkers, and treatment strategies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Molecular markers such as programmed death-ligand 1 (PDL-1), Breast Cancer gene 1-associated protein gene, and cyclin-dependent kinase inhibitor 2A (CDKN2A) have prognostic impact and should be considered for assessment in patient samples. In addition to histological subtype and tumor pattern, tumor volumetry plays an increasing important role in staging, assessment of treatment response, and prediction of survival. Several new blood-based biomarkers have been recently reported including peripheral blood DNA methylation, microRNAs, fibulin, and high-mobility group box 1, but have not been established in clinical routine use yet. Regarding treatment, targeted therapies, immunotherapy, and vaccination are considered as new promising strategies. Moreover, extended pleurectomy\/decortication is favored over extrapleural pneumonectomy (EPP) and intensity-modulated radiotherapy represents a possible approach in combination with EPP and pleurectomy\/decortication. Intracavitary treatment options are promising and deserve further investigations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Overall, there has not been a real breakthrough in the treatment of MPM. Further research and clinical trials are needed to evaluate outcome and to identify new potential treatment candidates.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000697","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T04:13:11Z","timestamp":1605586391000},"page":"80-86","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":59,"title":["Malignant pleural mesothelioma: recent developments"],"prefix":"10.1097","volume":"33","author":[{"given":"Katharina","family":"Sinn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Mosleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Alireza","family":"Hoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"Scherpereel","year":"2020","journal-title":"Eur Respir J"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3109\/08958378.2013.807321","article-title":"The role of genotoxicity in asbestos-induced mesothelioma: an explanation for the differences in carcinogenic potential among fiber types","volume":"25","author":"Barlow","year":"2013","journal-title":"Inhal Toxicol"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/gcc.22670","article-title":"Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes","volume":"57","author":"Betti","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","article-title":"Initial analysis of the international association for the study of lung cancer mesothelioma database","volume":"7","author":"Rusch","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.02.021","article-title":"Progress in the management of malignant pleural mesothelioma in 2017","volume":"13","author":"McCambridge","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"934","DOI":"10.21037\/tlcr-2019-pps-10","article-title":"Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma","volume":"9","author":"Hjerpe","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semcancer.2019.09.014","article-title":"Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies","volume":"61","author":"Hinz","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1158\/1078-0432.CCR-19-3573","article-title":"Telomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroup","volume":"26","author":"Pirker","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/bjc.2015.286","article-title":"Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis","volume":"113","author":"Kirschner","year":"2015","journal-title":"Br J Cancer"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N Engl J Med"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/his.13470","article-title":"Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma","volume":"72","author":"Rrapaj","year":"2018","journal-title":"Histopathology"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1471-2407-13-205","article-title":"Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma","volume":"13","author":"Tabata","year":"2013","journal-title":"BMC Cancer"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jtho.2018.10.163","article-title":"Peripheral blood DNA methylation as potential biomarker of malignant pleural mesothelioma in asbestos-exposed subjects","volume":"14","author":"Guarrera","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"8628612","DOI":"10.1155\/2019\/8628612","article-title":"MicroRNA signatures in malignant pleural mesothelioma effusions","volume":"2019","author":"Birnie","year":"2019","journal-title":"Dis Markers"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ajpath.2010.12.014","article-title":"Identification of novel markers for the diagnosis of malignant pleural mesothelioma","volume":"178","author":"Gueugnon","year":"2011","journal-title":"Am J Pathol"},{"key":"R16-20250526","first-page":"559","article-title":"Expression of thrombomodulin, calretinin, cytokeratin 5\/6, D2\u201340 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma","volume":"100","author":"Comin","year":"2014","journal-title":"Tumori"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"241","DOI":"10.21037\/atm.2017.05.23","article-title":"Volumetric assessment in malignant pleural mesothelioma","volume":"5","author":"Murphy","year":"2017","journal-title":"Ann Transl Med"},{"key":"R19-20250526","article-title":"Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma","author":"Ferdinandus","year":"2020","journal-title":"J Nucl Med"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2214\/AJR.11.7015","article-title":"Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume","volume":"198","author":"Gill","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jtho.2016.04.027","article-title":"North American multicenter volumetric CT study for clinical staging of malignant pleural mesothelioma: feasibility and logistics of setting up a quantitative imaging study","volume":"11","author":"Gill","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.athoracsur.2016.06.069","article-title":"A multicenter study of volumetric computed tomography for staging malignant pleural mesothelioma","volume":"102","author":"Rusch","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1183\/09031936.00146110","article-title":"Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?","volume":"38","author":"Frauenfelder","year":"2011","journal-title":"Eur Respir J"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00508-016-1080-z","article-title":"Management of malignant pleural mesothelioma \u2013 Part 1: Epidemiology, diagnosis, and staging: consensus of the Austrian Mesothelioma Interest Group (AMIG)","volume":"128","author":"Geltner","year":"2016","journal-title":"Wien Klin Wochenschr"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.athoracsur.2014.11.050","article-title":"Persistent lung expansion after pleural talc poudrage in nonsurgically resected malignant pleural mesothelioma","volume":"99","author":"Rena","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","article-title":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications","volume":"50","author":"Forest","year":"2018","journal-title":"Pathology"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification","volume":"11","author":"Galateau-Salle","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/his.14105","article-title":"Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma","volume":"77","author":"Bilecz","year":"2020","journal-title":"Histopathology"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","article-title":"The IASLC mesothelioma staging project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Nowak","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.jtho.2016.09.121","article-title":"The IASLC mesothelioma staging project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Rice","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","article-title":"The IASLC mesothelioma staging project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma","volume":"11","author":"Rusch","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1759-7714.2012.00127.x","article-title":"Multidisciplinary tor vergata university study group for malignant pleural M. Clinical and biologic prognostic factors in malignant pleural mesothelioma","volume":"3","author":"Ambrogi","year":"2012","journal-title":"Thorac Cancer"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.21037\/jtd.2016.07.55","article-title":"Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma","volume":"8","author":"Sandri","year":"2016","journal-title":"J Thorac Dis"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.2147\/CMAR.S201269","article-title":"High systemic immune-inflammation index represents an unfavorable prognosis of malignant pleural mesothelioma","volume":"11","author":"Ma","year":"2019","journal-title":"Cancer Manag Res"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/bjc.2014.478","article-title":"Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales","volume":"111","author":"Linton","year":"2014","journal-title":"Br J Cancer"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s12199-016-0530-6","article-title":"Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma","volume":"21","author":"Tanrikulu","year":"2016","journal-title":"Environ Health Prev Med"},{"issue":"(24 Suppl)","key":"R38-20250526","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2217\/fon.15.317","article-title":"Biomarkers and prognostic factors for malignant pleural mesothelioma","volume":"11","author":"Vigneri","year":"2015","journal-title":"Future Oncol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"259","DOI":"10.21037\/tlcr.2017.05.06","article-title":"Diagnostic and prognostic biomarkers for malignant mesothelioma: an update","volume":"6","author":"Chen","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1007\/s13277-015-4063-1","article-title":"Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma","volume":"36","author":"Liu","year":"2015","journal-title":"Tumour Biol"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"57460","DOI":"10.18632\/oncotarget.15404","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2147\/TCRM.S104077","article-title":"Are neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma?","volume":"12","author":"Tural Onur","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/JTO.0b013e31823f45c1","article-title":"Inflammation-based prognostic indices in malignant pleural mesothelioma","volume":"7","author":"Pinato","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/SLA.0b013e3182602af4","article-title":"Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis","volume":"256","author":"Ghanim","year":"2012","journal-title":"Ann Surg"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/JTO.0000000000000661","article-title":"A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma: a review of 12 years\u2019 experience","volume":"10","author":"Opitz","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.2147\/OTT.S113598","article-title":"Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date","volume":"10","author":"Levin","year":"2017","journal-title":"Onco Targets Ther"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2217\/fon-2017-0307","article-title":"A review of bevacizumab in the treatment of malignant pleural mesothelioma","volume":"13","author":"Brosseau","year":"2017","journal-title":"Future Oncol"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2018.06.026","article-title":"A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma","volume":"141","author":"Petrelli","year":"2018","journal-title":"Respir Med"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/annonc\/mdi187","article-title":"Second-line (poststudy) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"Manegold","year":"2005","journal-title":"Ann Oncol"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/1756-0500-5-482","article-title":"Re-challenge with pemetrexed in advanced mesothelioma: a multiinstitutional experience","volume":"5","author":"Bearz","year":"2012","journal-title":"BMC Res Notes"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J Clin Oncol"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1158\/1078-0432.CCR-17-2169","article-title":"A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma","volume":"23","author":"Zauderer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"280","DOI":"10.21037\/tlcr.2019.05.05","article-title":"A multicenter, randomized, phase II\/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial","volume":"8","author":"Belderbos","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3389\/fonc.2020.00777","article-title":"Cellular immunotherapy and locoregional administration of CAR T-cells in malignant pleural mesothelioma","volume":"10","author":"Belderbos","year":"2020","journal-title":"Front Oncol"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2017.04.004","article-title":"CAR T-cell therapy for lung cancer and malignant pleural mesothelioma","volume":"187","author":"Zeltsman","year":"2017","journal-title":"Transl Res"},{"key":"R59-20250526","article-title":"Abstract CT036: a phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: safety and efficacy","volume":"79","author":"Adusumilli","year":"2019"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, noncomparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"(Suppl 1)","key":"R62-20250526","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.21037\/tlcr.2019.11.23","article-title":"Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives","volume":"9","author":"Gray","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fonc.2020.00343","article-title":"Emerging treatments for malignant pleural mesothelioma: where are we heading?","volume":"10","author":"Cantini","year":"2020","journal-title":"Front Oncol"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.athoracsur.2014.05.071","article-title":"Extrapleural pneumonectomy after induction chemotherapy: perioperative outcome in 251 mesothelioma patients from three high-volume institutions","volume":"98","author":"Lauk","year":"2014","journal-title":"Ann Thorac Surg"},{"issue":"(Suppl 2)","key":"R68-20250526","doi-asserted-by":"crossref","first-page":"S285","DOI":"10.21037\/jtd.2017.10.16","article-title":"Surgery for malignant pleural mesothelioma: an international guidelines review","volume":"10","author":"Ricciardi","year":"2018","journal-title":"J Thorac Dis"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2013.11.026","article-title":"A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma","volume":"83","author":"Cao","year":"2014","journal-title":"Lung Cancer"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1097\/JTO.0b013e3181ed0489","article-title":"A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"5","author":"Cao","year":"2010","journal-title":"J Thorac Oncol"},{"key":"R71-20250526","first-page":"428","article-title":"Systematic review of trimodality therapy for patients with malignant pleural mesothelioma","volume":"1","author":"Cao","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"R72-20250526","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/JTO.0000000000000078","article-title":"A feasibility study evaluating surgery for mesothelioma after radiation therapy: the \u2018SMART\u2019 approach for resectable malignant pleural mesothelioma","volume":"9","author":"Cho","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R73-20250526","doi-asserted-by":"crossref","first-page":"232","DOI":"10.21037\/atm.2017.03.82","article-title":"Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P\/D)","volume":"5","author":"Batirel","year":"2017","journal-title":"Ann Transl Med"},{"issue":"(Suppl 2)","key":"R74-20250526","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.21037\/jtd.2017.10.165","article-title":"The role of intracavitary therapies in the treatment of malignant pleural mesothelioma","volume":"10","author":"Bertoglio","year":"2018","journal-title":"J Thorac Dis"},{"key":"R75-20250526","doi-asserted-by":"crossref","first-page":"100640","DOI":"10.18632\/oncotarget.22062","article-title":"Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"R76-20250526","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jtcvs.2019.07.073","article-title":"Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: a phase I trial","volume":"159","author":"Opitz","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R77-20250526","first-page":"472","article-title":"Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma","volume":"1","author":"Friedberg","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"R78-20250526","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.athoracsur.2016.08.071","article-title":"Extended pleurectomy-decortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years","volume":"103","author":"Friedberg","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"R79-20250526","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.athoracsur.2011.02.062","article-title":"Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma","volume":"91","author":"Friedberg","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"R80-20250526","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S0140-6736(14)60418-9","article-title":"Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial","volume":"384","author":"Rintoul","year":"2014","journal-title":"Lancet"},{"key":"R81-20250526","doi-asserted-by":"crossref","first-page":"e000123","DOI":"10.1136\/bmjresp-2015-000123","article-title":"Complications of indwelling pleural catheter use and their management","volume":"3","author":"Lui","year":"2016","journal-title":"BMJ Open Respir Res"},{"key":"R82-20250526","doi-asserted-by":"crossref","first-page":"e000368","DOI":"10.1136\/bmjresp-2018-000368","article-title":"MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial","volume":"6","author":"Matthews","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"R83-20250526","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J Clin Oncol"},{"key":"R84-20250526","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(16)30095-X","article-title":"Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial","volume":"17","author":"Clive","year":"2016","journal-title":"Lancet Oncol"},{"key":"R85-20250526","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/JTO.0b013e31827740f0","article-title":"Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma","volume":"8","author":"Gomez","year":"2013","journal-title":"J Thorac Oncol"},{"key":"R86-20250526","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jtcvs.2014.10.128","article-title":"Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma","volume":"149","author":"Baldini","year":"2015","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:06:23Z","timestamp":1748300783000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000697","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,12]]}}}